Phase 2 Respiratory Syncytial Virus Infections Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
Respiratory Syncytial Virus Infections+Metapneumovirus
GlaxoSmithKline1,808 enrolled4 locationsNCT07628049
Recruiting
Phase 2
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
Respiratory Syncytial Virus Infections
Shionogi192 enrolled80 locationsNCT07214571
Recruiting
Phase 2Phase 3
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
Respiratory Syncytial Virus Infections
Shanghai Ark Biopharmaceutical Co., Ltd.290 enrolled9 locationsNCT07658534
Recruiting
Phase 1Phase 2
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
Systemic Inflammatory Response SyndromeSARS CoV-2Respiratory distress syndrome+2 more
PEACHES BIOTECH50 enrolled3 locationsNCT06684379
Recruiting
Phase 1Phase 2
A Study of BLB-201 RSV Vaccine in Infants and Children
Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.137 enrolled15 locationsNCT05655182
Recruiting
Phase 1Phase 2
Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
Respiratory Syncytial Virus Infections
Ab&B Bio-tech Co., Ltd.JS470 enrolled1 locationNCT07582796
Recruiting
Phase 2
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
Respiratory Syncytial Virus Infections
GlaxoSmithKline184 enrolled37 locationsNCT07092865